Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 12:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 87 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: carbamazepine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Potential Drug Interaction Study Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel/Ethinyl Estradiol-containing Oral Contraceptives, and Carbamazepine

NCT06071442
View directory record Official record
Conditions
Healthy Participants
Interventions
Vemircopan, Rosuvastatin, Metformin, Levonorgestrel / Ethinyl Estradiol, Carbamazepine
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Terminated Phase 4 Interventional

DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder

NCT02623504
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Carbamazepine, Placebo
Drug
Lead sponsor
Validus Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Orlando, Florida • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

NCT05486949
View directory record Official record
Conditions
Healthy Subjects
Interventions
AZD4205 and carbamazepine, AZD4205 and itraconazole
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

NCT01703468
View directory record Official record
Conditions
Seizures
Interventions
Oxcarbazepine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 12:58 PM EDT
Approved For Marketing No phase listed Expanded access

Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects

NCT00918424
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine Extended Release
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
6
States / cities
Loxahatchee Groves, Florida • Palm Beach, Florida • Rockville, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

NCT01702623
View directory record Official record
Conditions
Seizures
Interventions
Oxcarbazepine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 30, 2026, 12:58 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

NCT06672900
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Carbamazepine, Itraconazole (Sporanox), ALG-000184
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir

NCT04962230
View directory record Official record
Conditions
Healthy Participant
Interventions
PF 07321332/ritonavir, Carbamazepine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

NCT06633419
View directory record Official record
Conditions
Healthy
Interventions
Opevesostat, Prednisone, Fludrocortisone acetate, Carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess LY4100511 (DC-853) in Healthy Adult Participants

NCT06345794
View directory record Official record
Conditions
Healthy
Interventions
LY4100511 (DC-853), Itraconazole, Fluconazole, Carbamazepine
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Not applicable Interventional Results available

Oxcarbazepine Versus Placebo in Childhood Autism

NCT00467753
View directory record Official record
Conditions
Autism
Interventions
Oxcarbazepine, Placebo/sugar pill
Drug · Other
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
5 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

NCT05581823
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Carbamazepine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Results available

Characterization of Epilepsy Patients BEEP 2b

NCT02707965
View directory record Official record
Conditions
Epilepsy
Interventions
Oxcarbazepine (brand name vs generic drugs), Divalproex Sodium (brand name vs generic drugs), Carbamazepine (brand name vs generic drugs), Lamotrigine (brand name vs generic drugs), levetiracetam (brand name vs generic drugs), Topiramate (brand name vs generic drugs), Zonisamide (brand name vs generic drugs), Phenytoin sodium (brand name vs generic drugs)
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 76 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

NCT01128959
View directory record Official record
Conditions
Epilepsy
Interventions
Intravenous Carbamazepine (IV CBZ)
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Torrance, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults

NCT02912364
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine, Carbamazepine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT00404248
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 3 Interventional Results available

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

NCT01713946
View directory record Official record
Conditions
Tuberous Sclerosis Complex-associated Refractory Seizures
Interventions
RAD001, Placebo, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 3 Interventional

Pediatric Epilepsy Study

NCT00050947
View directory record Official record
Conditions
Epilepsy
Interventions
oxcarbazepine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 16 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Madera, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2011 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

NCT06646042
View directory record Official record
Conditions
Healthy
Interventions
ibuzatrelvir, carbamazepine ER
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers

NCT00006395
View directory record Official record
Conditions
Healthy
Interventions
St. John's Wort
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants

NCT05994807
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DC-806, Itraconazole, Carbamazepine
Drug
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 30, 2026, 12:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3484356 in Healthy Female Participants

NCT04840888
View directory record Official record
Conditions
Healthy
Interventions
LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 30, 2026, 12:58 PM EDT
Not yet recruiting Phase 3 Interventional

Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study

NCT02219373
View directory record Official record
Conditions
Pediatric Chronic Neuropathic Pain
Interventions
Gabapentin, Oxcarbazepine, Placebo
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 12:58 PM EDT